Drugs / HS-10342
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04060511 | Jun 2019 → Dec 2020 | neoplasm | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05044988 | Sep 2021 → Dec 2022 | hormone receptor-positive breast cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10342 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04060511 ↗ |
| Action | Inhibit | “HS-10342 is a small molecular, oral potent, selective CDK4/6 inhibitor.” NCT04060511 ↗ |
| Modality | Small molecule | “HS-10342 is a small molecular, oral potent, selective CDK4/6 inhibitor.” NCT04060511 ↗ |
| Route | Oral | “given orally” NCT04060511 ↗ |
| Target | CDK4 | “HS-10342 is a small molecular, oral potent, selective CDK4/6 inhibitor.” NCT04060511 ↗ |